State Street
IBO

State Street’s Impact BioMedical IBO Stock Holding History

State Street’s Portfolio IBO Stock Details IBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$365K Buy
607,897
+596,100
+5,053% +$298K ﹤0.01% 3731
2025
Q4 		$5.96K Hold
11,797
– – ﹤0.01% 4280
2025
Q3 		$7.84K Hold
11,797
– – ﹤0.01% 4273
2025
Q2 		$7.63K Hold
11,797
– – ﹤0.01% 4247
2025
Q1 		$10.3K Buy
11,797
+626
+6% +$1.08K ﹤0.01% 4252
2024
Q4 		$16.2K Buy
+11,171
New +$23.2K ﹤0.01% 4250

Other funds holding IBO

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VGA
Vanguard Global Advisers Malvern, Pennsylvania $187B AUM
MAC
Mason & Associates (California) Los Angeles, California $619M AUM 29.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street's IBO Position: Q1 2026 in Review

State Street increased its Impact BioMedical (IBO) stake by 5,053% in Q1 2026, buying an estimated $298K and bringing the position to 607,897 shares worth $365K. The position accounts for ﹤0.01% of the portfolio, ranked #3731.

State Street first reported a position in IBO in Q4 2024 and has held it in 6 quarters since. 20 funds tracked by Wall St. Rank hold IBO as of Q1 2026.

  • State Street held 607,897 shares of Impact BioMedical worth $365K as of Q1 2026.
  • State Street bought 596,100 Impact BioMedical shares in Q1 2026, an estimated $298K.
  • Impact BioMedical made up ﹤0.01% of State Street's portfolio in Q1 2026, its #3731 holding.
  • State Street first reported a position in Impact BioMedical in Q4 2024 and has held it in 6 quarters since.
  • 20 funds tracked by Wall St. Rank held Impact BioMedical as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.